Self-destructive mechanism may lead to new tuberculosis drugs

Self-destructive mechanism may lead to new tuberculosis drugs

While the number of tuberculosis cases have steadily decreased since 1993, TB is still one of the world’s deadliest diseases, according to the tuberculosis statistics from the Centers for Disease Control and Prevention. One-fourth of the world’s population is infected with tuberculosis.

 

The World Health Organization estimates that 10 million people had tuberculosis in 2017, leading to 1.6 million TB-related deaths.

 

In 2018, in the United States, 9,029 new TB cases were reported, a 0.7% decrease from 2017. TB incidences in the U.S. in 2018 were the lowest numbers ever reported, and non-U.S.-born individuals accounted for two-thirds of those cases.

 

Although the United States has one of the lowest rates of TB worldwide, the disease remains one of the top 10 leading causes of death worldwide.

 

In efforts to find a better tuberculosis treatment, a group of scientists, led by Anabel Parret, have been studying a natural self-destructive mechanism found in the bacterium that causes TB.

 

“Our goal was to see the toxin-antitoxin system’s structure, so we could try to understand and even manipulate it,” explains Parret.

 

According to Medical News Today, after analyzing the behavior of the toxin-antitoxin system, the scientists found that when the toxin separates from its antidote, it becomes active and starts to destroy NAD+ molecules, which are crucial to the life of the cell.

 

Eventually, the degradation of the molecules kills all of the bacterial cells, one by one.

“If we find molecules that can disrupt the toxin-antitoxin system, and thus trigger cell death in TB patients, that would be the perfect drug,” says Parret. “If we succeed, this could be a new approach for treating TB and other infectious diseases.”

Orbis Biosciences strongly supports all industry efforts to save lives through research and innovation, such as a tuberculosis cure. Helping others is at the core of what we do at Orbis Biosciences. Our mission is to revolutionize the delivery, efficacy, and safety of pharmaceutical products, changing the way medicine is delivered.

While the number of tuberculosis cases have steadily decreased since 1993, TB is still one of the world’s deadliest diseases, according to the tuberculosis statistics from the Centers for Disease Control and Prevention. One-fourth of the world’s population is infected with tuberculosis.

 

The World Health Organization estimates that 10 million people had tuberculosis in 2017, leading to 1.6 million TB-related deaths.

 

In 2018, in the United States, 9,029 new TB cases were reported, a 0.7% decrease from 2017. TB incidences in the U.S. in 2018 were the lowest numbers ever reported, and non-U.S.-born individuals accounted for two-thirds of those cases.

 

Although the United States has one of the lowest rates of TB worldwide, the disease remains one of the top 10 leading causes of death worldwide.

 

In efforts to find a better tuberculosis treatment, a group of scientists, led by Anabel Parret, have been studying a natural self-destructive mechanism found in the bacterium that causes TB.

 

“Our goal was to see the toxin-antitoxin system’s structure, so we could try to understand and even manipulate it,” explains Parret.

 

According to Medical News Today, after analyzing the behavior of the toxin-antitoxin system, the scientists found that when the toxin separates from its antidote, it becomes active and starts to destroy NAD+ molecules, which are crucial to the life of the cell.

 

Eventually, the degradation of the molecules kills all of the bacterial cells, one by one.

“If we find molecules that can disrupt the toxin-antitoxin system, and thus trigger cell death in TB patients, that would be the perfect drug,” says Parret. “If we succeed, this could be a new approach for treating TB and other infectious diseases.”

Orbis Biosciences strongly supports all industry efforts to save lives through research and innovation, such as a tuberculosis cure. Helping others is at the core of what we do at Orbis Biosciences. Our mission is to revolutionize the delivery, efficacy, and safety of pharmaceutical products, changing the way medicine is delivered.

By | 2019-05-14T13:48:31-05:00 May 14th, 2019|Blog|0 Comments

About the Author: